Differences were also found between APS and the COVID-19 group II for all aPL (except anti-β2GPI IgA and aPS/PT IgA) and between APS and the COVID-19 group III (time of hospital discharge) for all except aCL IgG and IgM. The gene discussed is CD79A; the disease is autoimmune polyendocrinopathy.